Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512912-23-00

Acronym

BLCL-LEN-FDA-02

Enrollment

Registered

2024-06-19

Start date

Unknown

Completion date

2025-12-12

Last updated

2024-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No medical condition

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Portugal

None listed

Source: EU CTIS · Data processed: Feb 4, 2026